SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2005 / Cilt: 15 - Sayı: 4

The effect of transtuzumab treatment on time to development of brain metastasis and overall survival in patients with metastatic breast cancer

Metastatik meme kanserli hastalarda transtuzumab tedavisinin beyin metastazı gelişme süresi ve genel sağkalım üzerine etkisi

Canfeza SEZGİN
Erhan GÖKMEN
Pages
184–188
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we aimed to compare the time to development of brain metastasis, survival times after brain metastasis and overall survival (OS) times in patients with metastatic breast cancer (MBC) treated with and without trastuzumab.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, we aimed to compare the time to development of brain metastasis, survival times after brain metastasis and overall survival (OS) times in patients with metastatic breast cancer (MBC) treated with and without trastuzumab.
📊
Key Findings & Data:We evaluated 16 patients diagnosed as MBC with c-erbB-2 positive and developed brain metastasis during follow-up.
💡
Conclusion & Impact:By using trastuzumab in the treatment, control of systemic disease in patients with MBC is more feasible and survival rates are remarkably longer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Beyin neoplazmları · Sağkalım · Sağkalım oranı

Abstract

In this study, we aimed to compare the time to development of brain metastasis, survival times after brain metastasis and overall survival (OS) times in patients with metastatic breast cancer (MBC) treated with and without trastuzumab. We evaluated 16 patients diagnosed as MBC with c-erbB-2 positive and developed brain metastasis during follow-up. Seven patients were treated with trastuzumab containing regimen before development of brain metastasis while 9 patients were treated with regimen containing no trastuzumab. Median time to development of brain metastasis after detection of first metastasis and median OS time after having MBC was found to be longer in patients treated with trastuzumab (p=0.03 and p=0.0003, respectively). Although patients treated with trastuzumab had longer survival after development of brain metastasis, it did not have statistical significance (p=0.19). By using trastuzumab in the treatment, control of systemic disease in patients with MBC is more feasible and survival rates are remarkably longer.

Özet

Çalışmamızda metastatik meme kanseri (MMK) nedeni ile trastuzumab tedavisi alan ve almayan hastalardaki beyin metastazı gelişimine kadar geçen süre, beyin metastazı sonrası sağkalım ve genel sağkalım (GS) sürelerinin karşılaştırılması planlandı. c-erbB-2 ekspresse eden ve izleminde beyin metastazı gelişmiş 16 MMK’li hasta retrospektif olarak değerlendirildi. Yedi hastaya beyin metastazı gelişmeden önce trastuzumab içeren tedaviler uygulanırken, 9 hastaya trastuzumab içermeyen tedaviler verilmişti. İlk metastaz saptanmasından beyin metastazı gelişmesine kadar geçen medyan süre ile ilk sistemik metastaz saptandıktan sonraki medyan GS süresi trastuzumab alan hastalarda almayan hastalara göre daha uzun bulundu (sırasıyla p=0.03 ve p=0.0003). İstatistiksel olarak anlamlı olmamakla birlikte, beyin metastazı gelişimi sonrası sağkalım sürelerinin trastuzumab alan hastalarda daha iyi olduğu gözlendi (p=0.19). Trastuzumab tedavisi ile metastatik meme kanserli hastalarda sistemik hastalık daha iyi kontrol altına alınmakta ve sağkalım belirgin uzatılmaktadır.

🔖

Cite This Article

SEZGİN, C., GÖKMEN, E. (2005). The effect of transtuzumab treatment on time to development of brain metastasis and overall survival in patients with metastatic breast cancer. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 15 - Sayı: 4, 184–188. https://ajindex.com/articles/323097

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Benz CC, O'Hagan RC, Richter B, et al. HER2/neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15: 1513-1525,1997
  2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182, 1987
  3. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p 185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744, 1996
  4. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999
  5. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelobine in women with HER-2 overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
  6. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808, 2002
  7. Crown JP. The platinum agents: a role in breast cancer treatment? Semin Oncol 20(1 Suppl 3): 28-37, 2001
  8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 from metastatic breast cancer that overexpresses HER2. N Engl J Med 11: 783- 792,2001
  9. Takakura K, Sano K, Hojo S, et al. Metastatic tumors of the central nervous system. Tokyo: Igaku-Shoin, 1982
  10. DiStefano A, Yap HY, Hortobagyi GN, et al. The natural history of breast cancer patients with brain metastases. Cancer 44: 1913-1918, 1979
  11. Clayton AJ, Danson S, Jolly S, et al: Incidence of cerebral metastases in patients treated with trastuzumab fro metastatic breast cancer. Br J Cancer 91:639-643, 2004
  12. Lower EE, Drosick DR, Blau R, et al: Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 4:114-119, 2003
  13. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972-7, 2003
  14. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 11: 2349-2351, 2000
  15. Fokstuen T, Wilking N, Rutqvist LE, et al. Radiation ther